Positive News SentimentPositive NewsNASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis → AI Hell Will Break Loose [June 30, 2024] … (From Banyan Hill Publishing) (Ad) Free CNTX Stock Alerts $1.72 -0.06 (-3.37%) (As of 11:37 AM ET) Add Compare Share Share Today's Range$1.70▼$1.7650-Day Range$1.24▼$2.0452-Week Range$0.77▼$2.12Volume9,875 shsAverage Volume348,494 shsMarket Capitalization$129 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Context Therapeutics alerts: Email Address Context Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside237.1% Upside$6.00 Price TargetShort InterestHealthy1.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.36 out of 5 starsMedical Sector472nd out of 904 stocksPharmaceutical Preparations Industry220th out of 428 stocks 3.5 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.38% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 15,438.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 3.9 News and Social Media Coverage News SentimentContext Therapeutics has a news sentiment score of 1.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.Search Interest2 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Context Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.75) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill Publishing25% of Americans Are In Grave DangerAccording to this White House briefing … AI will replace up to 300 million jobs. That would amount to 25% of ALL jobs — worldwide But this isn’t a one-sided story…Click here for details. About Context Therapeutics Stock (NASDAQ:CNTX)Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More CNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTX Stock News HeadlinesMay 30, 2024 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateMay 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 16, 2024 | msn.comPiper Sandler Initiates Coverage of Context Therapeutics (CNTX) with Overweight RecommendationMay 16, 2024 | markets.businessinsider.comOptimistic Outlook for Context Therapeutics’ CTIM-76 Based on Targeting Efficacy and Market PotentialMay 11, 2024 | msn.comContext Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug TrialsMay 9, 2024 | investorplace.comCNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comContext Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 3, 2024 | msn.comContext Therapeutics Raises $100 Million in Private Placement to Propel Clinical TrialsMay 3, 2024 | msn.comContext Therapeutics Secures $100 Million in Private Placement to Fuel Clinical TrialsMay 2, 2024 | msn.comWall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than ExpectedMay 2, 2024 | finance.yahoo.comContext Therapeutics Announces $100 Million Private PlacementMay 2, 2024 | globenewswire.comContext Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76April 3, 2024 | msn.comContext Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer TherapyApril 2, 2024 | cnn.comContext Therapeutics, Inc.April 1, 2024 | markets.businessinsider.comContext Therapeutics Submits IND For CTIM-76April 1, 2024 | globenewswire.comContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersMarch 22, 2024 | markets.businessinsider.comBuy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug PositioningMarch 21, 2024 | investorplace.comCNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023March 21, 2024 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 21, 2024 | globenewswire.comContext Therapeutics Reports Full Year 2023 Operating and Financial ResultsDecember 27, 2023 | benzinga.comContext Therapeutics Stock (NASDAQ:CNTX), Short Interest ReportDecember 27, 2023 | benzinga.comContext Therapeutics Stock (NASDAQ:CNTX) Dividends: History, Yield and DatesNovember 28, 2023 | msn.comContext Therapeutics (CNTX) Price Target Increased by 21.31% to 3.77November 10, 2023 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNovember 10, 2023 | proactiveinvestors.comContext Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024See More Headlines Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/06/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+248.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-136.03% Return on Assets-109.54% Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book2.32Miscellaneous Outstanding Shares75,000,000Free Float65,773,000Market Cap$129 million OptionableNot Optionable Beta2.32 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Comp: $674.08kMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Comp: $504.14kMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Comp: $483.83kMr. Christopher Beck M.B.A.Senior Vice President of OperationsKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYMetacrineNASDAQ:MTCRCatalyst BiosciencesNASDAQ:CBIOHeron TherapeuticsNASDAQ:HRTXSIGA TechnologiesNASDAQ:SIGAView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Bought 133,357 shares on 5/29/2024Ownership: 1.478%View All Institutional Transactions CNTX Stock Analysis - Frequently Asked Questions Should I buy or sell Context Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CNTX shares. View CNTX analyst ratings or view top-rated stocks. What is Context Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1-year price targets for Context Therapeutics' shares. Their CNTX share price targets range from $4.50 to $10.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 237.1% from the stock's current price. View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts. How have CNTX shares performed in 2024? Context Therapeutics' stock was trading at $1.13 at the start of the year. Since then, CNTX stock has increased by 57.5% and is now trading at $1.78. View the best growth stocks for 2024 here. Are investors shorting Context Therapeutics? Context Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,010,000 shares, an increase of 15,438.5% from the April 30th total of 6,500 shares. Based on an average daily volume of 547,900 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.4% of the shares of the stock are short sold. View Context Therapeutics' Short Interest. When is Context Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our CNTX earnings forecast. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.15. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. Who are Context Therapeutics' major shareholders? Context Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (1.48%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTX) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
